Apellis Pharmaceuticals, Inc. (APLS) Institutional Ownership

Ownership Summary

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has 272 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 97.3% of Apellis Pharmaceuticals's outstanding shares in December 2025, up from 95.7% in September 2025.
• Their total shares held in APLS increased 7.48% from the prior quarter, while the number of investors in Apellis Pharmaceuticals increased 7.09% year over year.
• Among the 272 funds, 150 bought more Apellis Pharmaceuticals shares, 96 sold down, and 26 held their ground.
• The aggregate institutional position in Apellis Pharmaceuticals amounted to 126.5Mn shares as of December 2025, up by 8.81Mn shares quarter on quarter, and down 13.29Mn shares year over year.
• As of December 31, 2025, the biggest holder of Apellis Pharmaceuticals is WELLINGTON MANAGEMENT GROUP LLP at 12.72Mn shares, representing 9.78% of shares outstanding.
• The largest buyers of Apellis Pharmaceuticals for the quarter ending December 2025 were RTW INVESTMENTS, LP (7.67Mn), WELLINGTON MANAGEMENT GROUP LLP (3.43Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (1.26Mn), NORGES BANK (1.2Mn), Polar Capital Holdings Plc (1.06Mn).
• The largest sales of APLS for the quarter ending December 2025 came from JENNISON ASSOCIATES LLC (2.84Mn), AQR CAPITAL MANAGEMENT LLC (2.21Mn), Bank Of America Corp /De/ (2.0Mn), Amundi (1.46Mn), Ing Groep Nv (1.04Mn).
• Per Business Quant, the top 10 investors in APLS for the quarter ending December 2025 include WELLINGTON MANAGEMENT GROUP LLP (12.72Mn), Avoro Capital Advisors LLC (12.22Mn), VANGUARD GROUP INC (10.67Mn), Morgan Stanley (9.17Mn), Deep Track Capital, LP (7.75Mn), RTW INVESTMENTS, LP (7.67Mn), BlackRock, Inc. (6.26Mn), State Street Corp (4.61Mn), UBS Group AG (4.19Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (4.14Mn).